Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 13.50
Ask: 14.50
Change: -0.25 (-1.75%)
Spread: 1.00 (7.407%)
Open: 14.25
High: 14.00
Low: 13.75
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Venture Company

11 Feb 2005 07:00

Angle PLC11 February 2005 For Immediate Release 11 February 2005 ANGLE plc CUSTOMISER GROUP: NEW VENTURE COMPANY ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology, is pleased to announce the launch of its latestventure company, Customiser Group Ltd ('Customiser'). In accordance with ANGLE's Progeny(R) process for creating new ventures,Customiser has secured intellectual property utilising psychological profiling(more normally found in clinical psychology) and advanced pattern recognition.The approach has been developed and patented by a team of leading academicsacross a number of UK Universities. ANGLE expects to spend up to £500,000 inthis Progeny(R) venture. Global spend on the internet is now well in excess of $100bn per year andrevenues from internet advertising now exceed $10bn per year. The market fortailoring content to individual users is still in its infancy, but is alreadygenerating several hundred million dollars per annum in revenue and is widelypredicted to grow rapidly. Customiser's technology improves targeting of on-line advertising on internetportal sites, relevancy of search results and product recommendations withinretail sites. The Customiser solution produces substantially better resultsthan rivals which rely simply on data such as demographics and internet browsingbehaviour. It is expected that in the future, through Customiser's solution, internet userswill welcome personalised online adverts, search results and productrecommendations rather than wasting time with irrelevant information. Similarlyinternet advertisers and retailers will target personally meaningful adverts andproduct recommendations to receptive customers. Commenting on the collaboration with ANGLE, the technology development team'sAndrew Fraser, said: "We believe that internet personalisation will be worth several billion dollarsin the next few years and our collaboration with ANGLE will place us in anoutstanding position in this market." ANGLE's Chief Executive Andrew Newland said: "Customised on-line advertising and internet retailing are new but significantmarkets with enormous potential for growth. Customiser's solution offersincreased effectiveness in internet advertising, search results and productrecommendation placing us at the forefront of the rapidly emergingpersonalisation market." For further information ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveDawson Buck, Deputy Chief Executive Buchanan Communications 020 7466 5000Richard Darby, Suzanne Brocks Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales
10th Dec 20157:00 amRNSChange of FTSE Industry Classification Benchmark
30th Nov 20155:56 pmRNSHolding(s) in Company
17th Nov 20157:00 amRNSLung Cancer Research Publication
12th Nov 20152:17 pmRNSISSUE OF SHARE OPTIONS
14th Oct 20157:00 amRNSPatent Grant
30th Sep 20155:50 pmRNSResult of AGM
28th Sep 20157:00 amRNSOvarian cancer results
24th Sep 20157:00 amRNSProstrate cancer study published PLOS ONE Journal
9th Sep 20157:00 amRNSBREAST CANCER RESULTS PRESENTED AT CDX CONFERENCE
8th Sep 20153:54 pmRNSAnnual Report and Accounts and Notice of AGM
26th Aug 20151:48 pmRNSIssue of Equity and Total Voting Rights
23rd Jul 20157:00 amRNSFinal Results
20th Jul 20157:00 amRNSNotification of Preliminary Results
8th Jul 20157:00 amRNSAppointment Of Scientific Adviser
11th Jun 20157:00 amRNSBarts Prostate Cancer Update
3rd Jun 20157:00 amRNSAppointment of Scientific Adviser
26th May 20157:01 amRNSNew Patent Grants
21st Apr 20157:00 amRNSOvarian Cancer Update
20th Apr 20157:00 amRNSSidney Kimmel Cancer Centre
14th Apr 20157:00 amRNSIssue of Equity
4th Mar 20157:00 amRNSOffer to Shareholders
25th Feb 20151:11 pmRNSIssue of Equity
20th Feb 20154:05 pmRNSHolding(s) in Company
16th Feb 20157:01 amRNSMD Anderson Collaboration
16th Feb 20157:00 amRNSPlacing, Subscription and Offer
29th Jan 20157:00 amRNSInterim Results
27th Jan 20157:01 amRNS"Unprecedented Specificity" in Ovarian Cancer
23rd Jan 20157:00 amRNSCorporate Collaboration
23rd Jan 20157:00 amRNSPointMan collaboration with ANGLE plc
21st Jan 20153:00 pmRNSFurther information re Director's share transfer
19th Jan 20157:00 amRNSNotification of Interim Results
8th Jan 20157:00 amRNSCorporate Collaboration
15th Dec 20147:00 amRNSCancer Research Manchester Institute Publication
12th Nov 20147:00 amRNSFurther information re Director's share transfer
10th Nov 20147:00 amRNSIssue of Share Options
31st Oct 20147:00 amRNSADR PROGRAMME
21st Oct 20147:00 amRNSDirector's Share Transfer
17th Oct 20147:00 amRNSCollaboration with Barts Cancer Institute
17th Oct 20147:00 amRNSKey Opinion Leaders Report on Parsortix System
30th Sep 20144:30 pmRNSResult of AGM
30th Sep 20147:00 amRNSCollaboration with Thomas Jefferson University
25th Sep 20147:00 amRNSADR Programme, FDA Update and US Appointment
19th Sep 20147:00 amRNSBreast Cancer Collaboration
17th Sep 20147:00 amRNSCollaboration with Medical University of Vienna
8th Sep 20147:00 amRNSHamburg-Eppendorf Collaboration
4th Aug 20147:00 amRNSParsortix Granted Second US Patent
23rd Jul 20147:00 amRNSPreliminary Results
22nd Jul 20147:00 amRNSParsortix Evaluation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.